The era of biologics for children and young people with rheumatological disease
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The last decade has seen the management of children with juvenile idiopathic arthritis (JIA) transformed with the advent of anti-TNF therapies. The outlook and prognosis for children with severe arthritis is much improved over the last 10 years, Etanercept is still the only NICE approved biologic for children with JIA. But clinical trials in children have shown varying levels of efficacy with infliximab, adalimumab and abatacept as well. Systemic onset JIA (sJIA), a distinct subtype of JIA akin to adult onset stills disease (AOSD) has also seen dramatic advances with new biologicals such as anti-IL6 and anti-IL 1 therapies. Some of these agents are currently in ongoing multicentre international trials. Health care professionals caring for children with arthritis are working in an era of increasing number of biologic treatments for arthritis, yet with a lack of evidence base for how to predict those who will respond, to any individual drug, or those who will not. Without such biomarkers of prediction, we cannot yet practice 'personalised' medicine. Instead, we step through disease modifying agents, and then biologics, with choices led largely be availability or cost rather that what is ideal for each child. In this talk we will consider recent data that throw light on mechanisms of different disease subtypes in JIA review the current evidence base for biomarkers that identify mechanisms which underlie clinical heterogeneity of childhood arthritis, and then consider ongoing studies that aim to generate biomarkers for use in predicting response to therapy and ultimately to aid clinical choice for each child.
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Over one third of patients with Juvenile Idiopathic Arthritis (JIA) continue to have active disease into their adult years and it is not uncommon for de novo flares of disease to occur after years of remission. Many such patients warrant treatment with biologics and indeed many young people transfer to adult care having started their biologic treatment under the care of paediatric rheumatologists. Outcome studies and Registries are yet to report the long term impact and safety of biologics in JIA into adulthood and there is a paucity of studies reporting use of biologics in young adults with JIA. Current UK national guidance for the use of biologics in JIA does not extend into the adult years and there is no consensus as to the optimal use of different biologic agents in this age group and across the subtypes of JIA. In many instances the use of biologics is based on the extrapolation of studies in adults with rheumatoid arthritis and clearly for many patients their lives are transformed by the introduction of biologic agents. In this talk, we describe the need for Guidance on the optimal use of biologics in adult JIA subtypes, Guidance on the information needs for young people and their clinicians to inform decision making and Consensus policy statements to facilitate equitable access to these important group of drugs. There are now effective treatments for most patients with FMF, CAPS and DIRA and although not always quite as effective, good treatments are available for the remainder. Table 1 provides a summary of the genetics and treatments currently used for the hereditary autoinflammatory disorders.
This talk will provide a clinical overview of these major hereditary autoinflammatory diseases, current therapies, and will summarize an approach for the discovery of new genetic fever syndromes using emerging genetic technologies. Disclosures: The author has declared no conflicts of interest. Abstract not provided.
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Background: A ''National Arthritis Research Network'' is needed to encourage and enable most rheumatology and orthopaedic units to participate in clinical research studies. Increasing recruitment to clinical studies will be of crucial benefit to our speciality. Methods: Rheumatologists and orthopaedic surgeons need to enrol patients under their care into clinical research studies. Both randomised controlled trials and observational studies are important in furthering our understanding of the effects of treatment and therefore providing optimal clinical care. This presentation will consider ways in which the enrolment of patients into clinical research studies could be enhanced.
Results: Clinical research is challenging to deliver. Much of the current administrative work involved in setting up individual studies is repetitive. There are currently substantial delays involved in the process. By establishing a national research network it will be possible to reduce these delays to a minimum. This is because the network could ensure all relevant data is held in a secure on-line database and would not need to be collected repeatedly. It will also be possible to identify any specific causes of delay and to ensure these are overcome by concerted action. The Network will simplify the enrolment of patients into national clinical studies by: 
Conclusions:
The network should involve all the main constituents involved in promoting research in arthritis. This includes rheumatologists, orthopaedic surgeons, allied health professionals and funders. It should also take into account the needs of patient groups.
Although the concept of a network is under development, it has the potential to be a key method of helping specialists delivers their research goals. The views of BSR members are vital in defining how a register should be organised and function. There is a unique opportunity to streamline clinical research by acting in unison as a community and engagement of a range of BSR members, spanning senior consultants, trainees and allied health professionals, will prove invaluable.
